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The accumulation of advanced glycation end products is
thought to be a key factor in the initiation and progression of
diabetic nephropathy. Here we determined whether the size
of the ligands for the receptor for advanced glycation end
products (RAGEs) that were present in the serum of patients
with type 2 diabetes modulates their pathogenic potential.
Serum was collected from control subjects and patients
with type 2 diabetes with varying degrees of renal disease
(normo-, micro-, or macroalbuminuria). The titers of the RAGE
ligands N-carboxymethyllysine (CML), S100A, S100B, and
high-mobility group box 1 (HMGB1) were measured by
enzyme-linked immunosorbent assay in serum as well as in
pooled size-fractionated serum. We also measured cellular
binding of serum fractions to mesangial cells transfected with
RAGE and examined the downstream signaling pathways.
Circulating CML was increased in patients with type 2
diabetes, whereas HMGB1 was decreased. S100A8, S100BA9,
and soluble RAGE were unchanged. The high-molecular-
weight (over 50kDa) serum fraction contained the greatest
proportion of RAGE ligands, with all immunoreactivity
and cellular binding observed only with serum fractions
over 30kDa. High-molecular-weight serum from macro-
albuminuric patients showed greater RAGE binding capacity,
modulation of cell-surface RAGE expression, increased
phospho-protein kinase C-a, and p65 nuclear factor jB
DNA-binding activity, which were competitively inhibited
by soluble RAGE or CML neutralizing antibodies. These
data show that ligands that activate RAGE present in the
circulation of patients with type 2 diabetes and nephropathy
are predominantly of high molecular weight.
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Diabetic nephropathy is the most common cause of end-
stage renal disease in developed countries, with a key contri-
buting factor to its development and progression being the
accumulation of advanced glycation end products (AGEs).1
AGEs are a class of complex, heterogeneous compounds
formed as the result of nonenzymatic biochemical reactions,
including the Maillard reaction,2 whose accumulation is
accelerated in the presence of hyperglycemia and oxidative
stress.3 One of the most commonly identified AGEs present
in serum from patients with diabetes4 and in renal disease5 is
the nonfluorescent modification of lysine, N-carboxymethyl-
lysine (CML), common on circulating proteins such as
albumin. Indeed, tissue concentrations of CML have been
reported to be predictive of diabetic complications in
humans.6 Furthermore, therapies to decrease tissue concen-
trations of CML appear to be renoprotective in animal
models of diabetic nephropathy.7–10
AGEs can exert their biological effects in a number of
ways, including modulation of the receptor for advanced
glycation end products (RAGE). RAGE, a member of the
immunoglobulin superfamily, is a pattern recognition recep-
tor that binds various ligands, including S100/calgranulins,11
high-mobility group box 1 (HMGB1),12 and b-amyloid
sheets,13 and is involved in host–pathogen defense. Recently,
it has been postulated that the various pathways downstream
of RAGE, such as those involving nuclear transcription factor
kB (NF-kB),14 can be activated by multimeric or protein
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complexes of these ligands.15 Furthermore, in mouse models
of diabetes, genetic overexpression of RAGE leads to a decline
in kidney function and renal structural damage,16 which
is attenuated by therapies such as OPB-9195, which lower
CML accumulation. Conversely, mice with a genetic deletion
of RAGE appear to be protected against the development of
diabetic nephropathy.17,18 The purpose of this study was to
identify the pathogenic potential of circulating RAGE ligands
present in type 2 diabetic individuals with varying stages of
renal dysfunction.
RESULTS
Patient clinical characteristics
Table 1 summarizes key clinical characteristics of the diabetic
patients from whom the serum samples were obtained, strati-
fied by urinary albumin excretion rate (AER). There was no
difference in the glomerular filtration rate, age, duration of
clinically diagnosed type 2 diabetes, HbA1C, body mass index,
or lipid profile. The male/female ratio was 54–46%.
Control serum was obtained from 10 volunteers who were
recruited from within our laboratory and from within the
Baker IDI Heart & Diabetes Institute Gene Bank. The mean
age was 48±18 years, body mass index 26±5 kg/m2, 60%
were women, and AER was 6±8mg/min.
Circulating RAGE ligands are heterogeneous in diabetes
Patients with diabetes had an increase in circulating
CML concentrations when compared with control subjects
(Figure 1a). There was no change in serum S100A (Figure 1b)
or S100B (Figure 1c) in diabetic patients. In contrast,
circulating HMGB1 was decreased in patients with diabetes
when compared with control subjects (Figure 1d), whereas
serum soluble RAGE (sRAGE) was unchanged (Figure 1e).
RAGE ligands are only present in high-molecular-weight
fractions derived from human serum
RAGE ligands were next measured in size-fractionated
samples from pooled serum. Protein-bound CML was only
detected in serum fractions greater than 30 kDa in both
control and diabetic patients (Figure 2a). In addition, CML
content was significantly greater in high-molecular-weight
fractions (450 kDa) from diabetic sera when compared with
control sera (Figure 2a). Circulating S100A (Figure 2b) and
S100B (Figure 2c) proteins were only present in serum
fractions of greater than 50 kDa. HMGB1 was detected in the
30–50 kDa fraction derived from the control pool and the
high-molecular-weight (450 kDa) fraction from control and
diabetic patients, with the control fraction containing more
HMGB1 protein than that of the diabetic serum fraction
(Figure 2d). Western immunoblotting of serum under non-
reduced conditions confirmed that S100B (Figure 2e) and
HMGB1 (Figure 2f) were indeed present in the circulation
as high-molecular-weight proteins, and that HMGB1
appeared to increase in the diabetic patients in parallel with
degree of albuminuria. To investigate further, we performed
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) using
reduced serum, and revealed the presence of an HMGB1
protein complex at approximately 40 kDa (Figure 2g),
which was absent in the control pool, whereas a 70-kDa
protein complex was common to all groups. As RAGE has
been recently associated with IgG and HMGB1, western
immunoblotting of serum under nonreduced conditions
confirmed that IgG was also present at the same molecular
weight (Supplementary Figure S1, Supplementary Online
Appendix).
The RAGE-binding capacity of 125I-radiolabeled serum
fractions from control and diabetic patients (with known
Table 1 | Characteristics of type-2 diabetic patients with varying degrees of albuminuria
Normoalbuminuric Microalbuminuric Macroalbuminuric
n 20 20 20
Age (year) 65.8±14.0 69.8±12.1 65.0±8.67
Diabetes duration (year) 16 (10, 27) 14 (6, 23) 14 (9, 20)
HbA1C (%) 7.3±0.7 8.2±1.4 8.1±1.6
BMI (kg/m2) 29.9±4.9 33.6±8 32.3±5.9
AER (mg/min) 7.1 /C1.7 40.6 /C1.6 608.5 /C2.0
GFR (ml/min per 1.73m2) 85.5±35.1 67.9±24.6 74.7±28.4
Total cholesterol (mmol/l) 3.9±1.0 4.2±0.9 4.1±1.1
LDL cholesterol (mmol/l) 2.2±0.8 2.9±1.7 2.3±0.7
HDL cholesterol (mmol/l) 1.1±0.3 1.0±0.4 1.1±0.5
Triglycerides (mmol/l) 1.0 (0.7, 1.3) 1.2 (1.0, 2.1) 1.25 (0.8, 3.1)
Medication use (%)
Insulin 20 5 20
ACE inhibitors 20 20 25
ARBs 20 5 30
b-Blockers 5 5 20
Statins 80 85 75
Abbreviations: ACE, angiotensin-converting enzyme; AER, albumin excretion rate; ARB, angiotensin receptor blocker; BMI, body mass index; GFR, glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Data are mean±s.d., except for the following: Albumin excretion rate (AER) is shown as the geometric mean  /C tolerance factor; diabetes duration and triglycerides are
presented as medians (25th, 75th quartile).
Patients were classified as normoalbuminuric (normo, AERo20 mg/min), microalbuminuric (micro, AER 20-200 mg/min), or macroalbuminuric (macro, AER X200 mg/min).
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nephropathy—pooled from micro- and macroalbuminuric
patients) was next examined in primary renal mesangial cells
overexpressing human full-length RAGE. High-molecular-
weight serum fractions (450 kDa) from both diabetic and
control individuals had significantly increased cellular
binding to RAGE overexpressing cells (Figure 2h) when
compared with medium-molecular-weight (MMW) serum
fractions (30–50 kDa, containing minimal RAGE ligands).
There was no binding to RAGE overexpressing cells detected
in other serum fractions (data not shown).
Cellular binding of high-molecular-weight serum frac-
tions after stratification for albuminuria was next studied in
primary rat mesangial cells overexpressing either human
RAGE (AdRAGE) in the presence or absence of soluble RAGE
(AdsRAGE). 125I-labeled high-molecular-weight micro- and
macroalbuminuric serum fractions had increased binding to
RAGE-overexpressing mesangial cells when compared with
normoalbuminuric high-molecular-weight serum fractions
(Figure 2i), which was prevented by coinfection with an
adenovirus that secretes sRAGE (Figure 2i, hatched bar,
AdsRAGE þ ). In addition, there was a decrease in cellular
binding of the control high-molecular-weight fraction to cells
overexpressing sRAGE. Competitive binding with  100
excess of unlabeled serum fractions decreased cellular binding
by 60–70% (data not shown).
Modified albumin is abundant in high-molecular-weight
serum pools derived from patients with diabetes
Non-fractioned and serum pools fractionated by molecular
weight from control () and diabetic (þ ) patients (with
micro- and macroalbuminuria, pooled) were subjected to
SDS–PAGE under reducing conditions (Figure 3a). CML-
modified bovine serum albumin (BSA) (CML-BSA) was
used as a positive control (far right-hand lane). The serum
pool from diabetic patients contained a number of high-
molecular-weight protein bands, which were not prominent
in the control pool (Figure 3a). Indeed, immunoblotting
revealed that serum albumin from patients with diabetes
and albuminuria contained a significantly greater number
of CML modifications (Figure 3b). The specific ion spray
spectra (Figure 3d–f) showed that there was a prominent
peak present as part of the albumin spike at approximately
73–78 kDa, which was not evident in the serum pools from
control individuals (Figure 3d). Furthermore, this spike
was also identified in the spectrum of CML-modified BSA
(Figure 3c), used as a positive control. Ion spray spectra
from diabetic patients with micro- and macroalbuminuria
contained the same peak (Figure 3e and f).
High-molecular-weight ligands present in diabetic serum
modulate renal mesangial cell RAGE expression and
signaling
To investigate if the high-molecular-weight fraction isolated
from serum of healthy individuals or patients with type 2
diabetes can induce pathogenic changes in vitro, we exposed
primary renal mesangial cells to high-molecular-weight
serum fractions for 7 days. The high-molecular-weight
serum treatment was equivalent to 100 mg/ml CML-BSA, as
measured previously by enzyme-linked immunosorbent assay
(ELISA). In addition to high-molecular-weight serum treat-
ment, cells were treated with or without plant-derived
sRAGE (1 mg/ml) or a neutralizing CML antibody (1mg/ml).
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Figure 1 |Receptor for advanced glycation end product (RAGE) ligands present in human serum. RAGE ligands were determined
in the serum from patients with type 2 diabetes. (a) Circulating N-carboxymethyllysine (CML) was determined by enzyme-linked
immunosorbent assay (ELISA). (b) Circulating S100A was measured by enzyme immunoassay. (c) Serum S100B was determined by enzyme
immunoassay. (d) HMGB1 was measured by ELISA. (e) Soluble RAGE concentration as determined by ELISA. D, Individuals with type 2
diabetes; C, age-matched controls; normo, normoalbuminuria (o20 mg/min/day); micro, microalbuminuria (20–200 mg/min/day); macro,
macroalbuminuria (4200 mg/min/day); n¼ 20 per group. *Po0.05 vs control.
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There was no change in cell-surface RAGE expression on
mesangial cells after exposure to high-molecular-weight
serum fractions from diabetic patients when compared with
control subjects (Figure 4a and b). However, cell-surface
RAGE expression increased when cells were exposed to high-
molecular-weight serum fractions derived from patients
with macroalbuminuria when compared with those with
normoalbuminuria, (Figure 4a) which was prevented by
either sRAGE or CML neutralizing antibodies. When sRAGE
was coincubated with high-molecular-weight serum fractions
derived from normoalbuminuric patients, there was a modest
increase in cell-surface RAGE expression compared with the
nontreated normoalbuminuric group (Figure 4a).
The effect of high-molecular-weight fractions on NF-kB
DNA-binding activity in renal mesangial cells was deter-
mined. There was increased activation of the p65 subunit of
NF-kB in mesangial cells exposed to high-molecular-weight
serum fractions derived from both microalbuminuric and,
to a greater extent, macroalbuminuric patients when com-
pared with control subjects (Figure 4c and d), which were
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Figure 2 |Receptor for advanced glycation end product (RAGE) ligands in human serum fractions and renal cellular binding.
(a–d) Serum from control and diabetic patients was separated by molecular weight centrifugal filters, and RAGE ligands were measured
in control and diabetic serum fractions. (a) Serum N-carboxymethyllysine (CML), (b) serum S100A, (c) serum S100B, (d) serum HMGB1.
(e–f) Western immunoblotting of (e) S100B and (f) HMGB1 proteins from total (non-fractionated) serum stratified by albuminuria and
glomerular filtration rate (GFR; 4oro60ml/min per 1.73m2) under nonreducing conditions. (g) Western immunoblotting of HMGB1
proteins from total (non-fractionated) serum under reducing conditions. (h and i) Binding of 125I-radiolabeled serum fractions to primary rat
mesangial cells. (h) Binding of 125I-radiolabeled medium-molecular-weight (MMW) (30–50 kDa) and high-molecular-weight (HMW) (450)
fractions from pooled micro- and macroalbuminuric diabetic or control individuals to primary rat mesangial cells overexpressing human full-
length RAGE. (i) Binding of 125I-radiolabeled HMW serum fractions from control or normo-, micro-, or macroalbuminuric patients to primary
rat mesangial cells overexpressing either human soluble RAGE (AdsRAGE) or human full-length RAGE (AdRAGE), n¼ 3–6 serum pools
per fraction. *Po0.05 vs control 450 kDa fraction, wPo0.05 vs serum fractions 30–50 kDa, zPo0.05 vs control AdRAGE, yPo0.05 vs
normoalbuminuric AdRAGE, 8Po0.01 vs MMW (30–50 kDa) serum fractions.
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attenuated by concomitant administration of either sRAGE
(Figure 4c) or a CML neutralizing antibody (Figure 4d).
Administration of sRAGE increased the activation of the
p65 subunit of NF-kB in mesangial cells exposed to high-
molecular-weight serum from control and diabetic indivi-
duals with normo- and microalbuminuria (Figure 4c).
There was a decrease in the secretion of vascular
endothelial growth factor from primary mesangial cells
treated with high-molecular-weight serum fractions from
diabetic patients with micro- and macroalbuminuria when
compared with normoalbuminuric or control individuals
(Figure 4e and f), which was unaffected by sRAGE.
Neutralization of CML with an antibody further decreased
the secretion of vascular endothelial growth factor from cells
exposed to high-molecular-weight serum from patients with
macroalbuminuria (Figure 4f).
A key downstream signaling molecule of RAGE in the
kidney is protein kinase C (PKC). There was no change in
plasma membranous PKC activity in mesangial cells exposed
to high-molecular-weight serum fractions derived from
patients with diabetes (data not shown). However, phos-
phorylated PKC-a/total PKC-a ratio was increased in
mesangial cells exposed to high-molecular-weight serum
fractions from diabetic patients with normo-, micro-, and
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Figure 3 |Analysis of high-molecular-weight proteins from sera. (a) Non-fractionated (NF) and fractionated serum pools from either
control () or diabetic (þ ) patients with renal impairment were separated by SDS–polyacrylamide gel electrophoresis (PAGE) and stained
with Coomassie blue. N-carboxymethyllysine (CML)-bovine serum albumin (BSA) was used as a positive control (far right lane). Lanes 1 and
8 are molecular weight markers. (b) Western immunoblotting and quantification of the ratio of CML-modified albumin (selected by
immunoprecipitation with an anti-CML antibody) to nonglycated albumin in human serum pools. (c–f) Spectra after ion spray MS/MS of
(c) CML-modified BSA as a positive control, (d) pooled control sera, (e) pooled sera from microalbuminuric patients, and (f) pooled sera
from macroalbuminuric patients. *Po0.05 vs control group.
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macroalbuminuria and was attenuated with sRAGE treat-
ment (Figure 5a and b).
DISCUSSION
Antagonism of the RAGEs is a target under active investi-
gation for the treatment of diabetic complications in humans
(http://www.clinicaltrials.gov/ct2/show/NCT00287183?term=
NCT00287183&rank=1). Although a number of previous
studies have assessed both circulating RAGE ligands and
sRAGE concentrations in human cohorts of diabetic nephro-
pathy, conflicting data have been reported.19–21 For the first
time, in this study, we have not only directly analyzed the levels
of various RAGE ligands but have also identified that their
pathogenic potential may be greatest when they are part of the
high-molecular-weight multimeric structures or are associated
with proteins. Furthermore, it is evident that there are disparate
effects of these high-molecular-weight ligands in human serum
on RAGE-dependent downstream signaling pathways, such as
PKC-a and p65 NF-kB, dependent on the degree of renal
dysfunction present.
In this study, we identified that almost all of the
immunoreactivity for the RAGE ligands studied, namely
HMGB1, S100A, S100B, and CML, was present within
molecular weight fractions of greater than 50 kDa. For S100/
calgranulins, a previous study has shown that these molecules
form multimeric structures to ligate with RAGE, although
these studies were not performed in the diabetic context.22
Other previous work has suggested that circulating HMGB1
is bound with DNA fragments (CpG-A ODN) from necrotic
cells and immune complexes in patients with systemic lupus
erythematosus, which facilitates and enhances the binding of
HMGB1 to RAGE.15 Indeed, our these data are the first to
suggest that HMGB1 exists in serum of diabetic patients in
concert with other proteins. Not surprisingly, there was no
immunoreactivity for HMGB1 observed in serum fractions
of less than 30 kDa in type 2 diabetic patients. In addition,
western immunoblots of non-fractioned serum under non-
reducing conditions confirmed that HMGB1 protein in the
circulation of diabetic patients exists mostly as a complex of
greater than 100 kDa. Binding of HMGB1 to circulating
immune complexes may selectively switch HMGB1 binding
from Toll-like receptors 2 and 4 to RAGE as has been
reported in systemic lupus erythematosus.15 Interestingly,
the total serum concentrations of HMGB1, which are almost
exclusively high-molecular-weight within this study and IgG
associated, are actually decreased in the serum of diabetic
patients when compared with controls. This is in contrast to
recent study that found increased circulating concentrations
of HMGB1 in diabetic patients,23 though these patients had
type 1 diabetes. In this study, however, when serum was
separated by SDS–PAGE the complexed HMGB1 appeared to
be increased in diabetic patients with renal disease. Moreover,
separation of chemically reduced serum samples revealed the
appearance of an HMGB1 protein band at approximately
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Figure 4 |High-molecular-weight proteins in diabetic serum differentially modulate receptor for advanced glycation end product
(RAGE) expression and signaling in primary renal mesangial cells. Primary mesangial cells were exposed to high-molecular-weight
(HMW) serum fractions from patients with type 2 diabetes with varying degrees of albuminuria for 7 days. The HMW serum treatment was
equivalent to 100mg/ml N-carboxymethyllysine (CML), as measured previously by enzyme-linked immunosorbent assay (ELISA). In addition
to HMW serum treatment, cells were treated with or without plant-derived soluble RAGE (sRAGE) (1 mg/ml) or neutralizing CML antibody
(1 mg/ml). Experiments were performed in duplicate with n¼ 4 per group/experiment. (a and b) Cell-surface RAGE expression by flow
cytometry in the presence and absence of (a) sRAGE and (b) neutralizing CML antibody (a-CML). (c and d) p65 nuclear factor kB (NF-kB)
DNA-binding activity in the presence and absence of (c) sRAGE and (d) neutralizing CML antibody. (e and f) Secretion of vascular endothelial
growth factor (VEGF) in the presence and absence of (e) sRAGE and (f) neutralizing CML antibody. *Po0.05 vs untreated normoalbuminuric,
wPo0.05 vs untreated macroalbuminuric, zPo0.05 vs untreated control, yPo0.05 vs untreated microalbuminuric, 8Po0.05 vs micro
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40 kDa, which was absent in the control participants. This
may indicate the existence of an alternate complex, though
this was not associated with the degree of albuminuria, and
the role of this complex in the kidney cannot be deduced by
this study.
Hence, because the serum concentrations of S100/
calgranulins also appear to be decreased in diabetic patients,
it is more likely that the source of RAGE stimulation and
signaling by PKC-a and p65 observed within this study with
micro- and macroalbuminuric serum is by other RAGE
ligands such as CML-modified proteins including albumin.
Indeed, we identified increases in CML modification of
albumin in serum from type 2 diabetic patients. This is
further supported by our findings that these specific path-
ways were blocked not only by sRAGE, which acts as a decoy
for ligand binding, but also with anti-CML antibodies.
In type 2 diabetes, other studies have suggested that
modification of circulating serum albumin is an important
contributor to the pathogenesis of complications such as
renal disease.24,25 Indeed, in our control sera there appears to
be minimal modification of the albumin present when
compared with that seen in sera from diabetic subjects,
consistent with findings from other investigators.26 However,
our data indicate that not only is albumin heavily modified
(increasing its molecular weight) but also that a large
majority of these modifications are related to CML, with
an almost identical albumin spectral peak identified in these
patients’ sera as that observed in exogenously prepared CML-
modified BSA. It is likely that not only is the CML-modified
albumin increased in serum from macroalbuminuric patients
but also that this process may also affect the catabolism and
turnover of albumin in these patients, shifting albumin from
the extravascular to the vascular compartment and thereby
prolonging the source of RAGE stimulation.
Our current data show that high-molecular-weight serum
fractions had significantly increased cellular binding to
RAGE-overexpressing cells when compared with MMW
serum fractions containing minimal RAGE ligands. There
was no binding to RAGE-overexpressing cells detected in
other serum fractions. It is well recognized that larger
proteins contain more binding sites than smaller proteins
and thereby could theoretically display a higher affinity for
ligand binding to RAGE. Indeed, the RAGE ligands studied,
CML, S100A and S100B, and HMGB1, are polyvalent
ligands. HMGB1 also binds to Toll-like receptor 2 and
Toll-like receptor 4.27 S100A8 (calgranulin A) and S100A9
(calgranulin B) seem to bind and activate various cell-surface
receptors such as heparan sulfate proteoglycans, CD36, and
RAGE.28 It has been proposed that multimeric forms of S100
proteins trigger aggregation of RAGE, thereby activating
intracellular signaling cascades.28 Not only does our study
show a greater binding capacity of high-molecular-weight
serum to RAGE, but it also provides evidence that serum
fractions from patients with renal disease bind RAGE, and
perhaps have a higher affinity for RAGE, more than serum
fractions from patients without renal disease. Moreover, these
fractions are functionally active as shown by our in vitro
studies in primary mesangial cells.
The differential effects of circulating RAGE ligands present
within the serum of type 2 diabetic patients with varying
degrees of renal dysfunction highlight the importance of
investigating temporal changes in pathogenic mediators
during the development of a chronic disease such as diabetic
nephropathy. One would suggest that these findings are
directly relevant for the design of antagonists for this
multiligand receptor, because the circulating RAGE ligands
with the most pathogenic potential identified in this study
were all complex structures, being multimeric or protein-
associated and therefore of high molecular weight. It appears
that the use of RAGE antagonists in individuals with
macroalbuminuria as a result of type 2 diabetes are likely
to be most helpful and should be considered a novel rational
approach to treat this disorder.
MATERIALS AND METHODS
An expanded version of the ‘research design and methods’ is
available in Supplementary Online Appendix containing details of
SDS–PAGE, western immunoblotting, ion trap LC-MS/MS, cell
lysate preparation, 125I radioligand binding assay, flow cytometry,
PKC activity, vascular endothelial growth factor, ELISA, and NF-kB
DNA-binding activity.
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Figure 5 |High-molecular-weight proteins in diabetic serum
stimulate protein kinase C-a (PKC-a) activity in primary renal
mesangial cells. Primary mesangial cells were exposed to high-
molecular-weight (HMW) serum fractions from patients with type
2 diabetes as described in Figure 4. In addition to HMW serum
treatment, cells were treated with or without plant-derived
soluble RAGE (sRAGE) (1 mg/ml). (a) Representative immunoblots
stained for phosphorylated PKC-a (82 kDa; top) and PKC-a (80 kDa;
bottom). (b) Quantitation of phosphorylated PKC-a and PKC-a
activity expressed as a ratio. The graph represents the densito-
metric analysis of individual western blots expressed as relative
optical density. *Po0.05 vs untreated normoalbuminuric,
wPo0.05 vs untreated macroalbuminuric, zPo0.05 vs untreated
control.
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Patient sample collection
Serum samples were drawn from a collection of type 2 diabetic
patients with varying degrees of albuminuria and compared with
matched control patients. Patients were classified as normoalbumi-
nuric (normo, AERo20mg/min), microalbuminuric (micro, AER
20–200 mg/min), or macroalbuminuric (macro, AERX200mg/min).
The glomerular filtration rate was measured isotopically using
99Tc-DTPA and was expressed per 1.73m2 of body surface area.
Fasting lipids were measured by enzymatic colorimetry. Total
cholesterol was measured by enzymatic colorimetric methods,
and low-density lipoprotein-cholesterol was calculated using the
Friedewald equation. As the primary referral base for these
participants was from general practitioners, with only 20% referred
directly from within the hospital, the cohort is considered
representative of the general diabetes population. Blood and urine
were collected as part of routine examination, with albumin excretion
rate determined from a 24h urine collection and HbA1C each assayed
at the time of sample collection. All procedures were in accordance
with the Declaration of Helsinki Principles and were approved by the
Austin Health Human Ethics Committee. Control serum was obtained
from 10 volunteers who were recruited fromwithin the laboratory and
from within the Baker IDI Heart & Diabetes Institute Gene Bank.
Size fractionation of serum samples
Sera were pooled and enriched for specific molecular weight fractions
using Amicon Ultra-15 Centrifugal Filter devices (Millipore, Bedford,
MA, USA). Briefly, 15ml of serum from control (serum from n¼ 10
patients, pooled), normoalbuminuric (n¼ 84 patients pooled),
microalbuminuric (n¼ 84 patients pooled), or macroalbuminuric
(n¼ 35 patients pooled) patients were added to a 50-kDa molecular
weight cutoff filter column and centrifuged for 3000g for 1 h. The
concentrate was collected (450 kDa fraction, high molecular weight)
and the ultrafiltrate was transferred to a 30-kDa molecular weight
cutoff filter column and centrifuged for a further 10min at 3000g.
The concentrate was collected (30–50 kDa fraction, MMW) and the
ultrafiltrate was transferred to a 5-kDa molecular weight cutoff filter
column and centrifuged for 40min at 3000g. The concentrate
(5–30 kDa fraction) and ultrafiltrate (o5 kDa fraction) were
collected. These individual serum fractions representing molecular
weights o5, 5–30, 30–50, and 450 kDa were stored at 80 1C.
Cell culture
Mesangial cells were isolated from kidneys of Sprague–Dawley rats as
previously described.17 Isolated cells were cultured in Dulbecco’s
modified Eagle’s medium (with no phenol red), supplemented with
2mmol/l glutamine, 5000U/ml penicillin/streptomycin, and 20%
fetal bovine serum. Cells were passaged weekly for up to 10 passages.
For the RAGE expression and signaling studies, mesangial cells were
cultured in high glucose conditions (25mmol/l D-glucose) for 7 days
with either control, normo, micro, or macro high-molecular-weight
pooled serum prepared as described above. The content of the
physiologically relevant AGE, CML, was determined in the high-
molecular-weight serum fractions by ELISA as described below.
High-molecular-weight serum fractions were administered to cells at
a dose equivalent to 100mg/ml of CML. In addition, cells were
treated with or without plant-derived sRAGE (sRAGE) (1 mg/ml) or
neutralizing CML antibody (1 mg/ml).
RAGE ligand determination
Out of the total serum samples collected, we randomly sampled 20
serum samples per group in which to determine RAGE ligands.
CML concentrations in total serum and serum fractions were
measured by ELISA as previously described.29 Calgranulins A
(S100A8) and B (S100A9) were measured in total serum and in
serum fractions using commercially available MRP8 (for calgranulin
A) or MRP14 (for calgranulin B) enzyme immunoassay kits (BMA
Biomedicals, Augst, Switzerland). HMGB1 was measured in total
serum and in serum fractions using an HMGB1 ELISA (ShinoTest,
Kanagawa, Japan). sRAGE was measured in total serum using a
RAGE sandwich ELISA (R&D Systems, Minneapolis, MN, USA).
Statistics
All statistical computations were performed using GraphPad Prism
version 4.0a for Mac OS X (GraphPad Software, San Diego, CA,
USA). Values of experimental groups are shown as mean ± s.e.m.
unless otherwise stated. One-way analysis of variance with Tukey’s
post hoc test analysis was used to determine statistical significance.
Where appropriate, either two-tailed t-tests or Mann–Whitney
U-tests were performed. A probability of Po0.05 was considered
to be statistically significant.
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